Companies / Congruence Therapeutics
Congruence Therapeutics
Congruence Therapeutics is a health and biotech AI company based in Montréal, Quebec. It had raised US$71.5M as of November 2026, most recently a US$39.5M venture round in March 2026 led by Dimension and OrbiMed.
Computationally driven drug discovery using its Revenir platform (biophysics and machine learning) to design small-molecule correctors for protein-misfolding diseases.
congruencetx.com- Founded
- 2021
- Category
- Health/
Bio AI - Status
- Active
- Disclosed raised
- US$71.5M
Funding history
| Round | Date | Amount | Investors |
|---|---|---|---|
| Venture round | Mar 19, 2026 | US$39.5M | Dimension and OrbiMed (co-leads); Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, Driehaus Capital Management, Silver Arc Capital. Co-led by Dimension (new) and OrbiMed; Amplitude Ventures, FSTQ, Lumira, Investissement Québec, BDC Thrive Venture Fund, Driehaus and Silver Arc participated |
| Venture round | Sep 4, 2025 | US$32M | Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, OrbiMed, Driehaus Capital Management, Silver Arc Capital, Alexandria Venture Investments. Insider round from existing investors (Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, Alexandria) to fund the CGX-926 Phase 1. Announcement date per BioWorld Sep 5 2025 coverage, to confirm |
Founders
- Clarissa Desjardins, Co-founder/CEO.
Sources
Data as of November 10, 2026.